Managing Anemia: Point of Convergence for Heart Failure and Chronic Kidney Disease?

Area of Science:

• Cardiology
• Nephrology
• Hematology

Background:

• The cardiorenal syndrome (CRS) involves a complex interplay between chronic heart failure (HF) and chronic kidney disease (CKD).
• Anemia is a prevalent comorbidity in CRS, affecting 5% to 55% of patients with advanced HF and CKD.
• Anemia exacerbates both cardiac and renal dysfunction through mechanisms like reduced oxygen transport and tissue hypoxia.

Purpose of the Study:

• To review current and emerging therapeutic strategies for managing anemia in patients with cardiorenal anemia syndrome (CRSA).
• To explore novel treatment options beyond traditional hemoglobin-focused therapies.

Main Methods:

• This review synthesizes findings from recent clinical trials and research on anemia in the context of CRS.
• It examines the physiopathological mechanisms linking HF, CKD, and anemia.

Main Results:

• Anemia prevalence increases with the severity of HF and CKD.
• Key mechanisms include reduced erythropoietin production and impaired oxygen transport, leading to hypoxia and worsening cardiorenal function.
• New therapeutic agents, including hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors and hepcidin antagonists, show promise.

Conclusions:

• CRSA presents significant challenges due to its high morbidity and mortality.
• Novel therapeutic agents targeting HIF-PH pathways and hepcidin offer potential advancements in CRSA management.
• Further research is needed to establish the efficacy and safety of these new treatments.